Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Extension to Study TRCA-301

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completed the 12-week treatment period and attended the Week 12 Visit in the parent study TRCA-301.~* Blood bicarbonate level of \>= 12 mEq/L at the Week 12 Visit in the parent study TRCA-301.~Key Exclusion Criteria:~* Any level of low blood bicarbonate at the Week 12 Visit that, in the opinion of the Investigator, requires emergency intervention or evaluation for an acute acidotic process.~* Required dialysis for acute kidney injury or worsening CKD during the parent study TRCA-301.~* Planned initiation of renal replacement therapy within 6 months following study entry.~* History or current diagnosis of diabetic gastroparesis, bowel obstruction, swallowing disorders, severe gastrointestinal disorders, inflammatory bowel disease, major gastrointestinal surgery, or active gastric/duodenal ulcers.~* Serum calcium \<= 8.0 mg/dL at the Week 10 in the parent study TRCA-301.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- TRC101 (Type: EXPERIMENTAL): Administered once daily (QD) for 40 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Administered once daily (QD) for 40 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).